PapersPMID:40918053
Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial.
What moved
1 findingHow to read these marks →“Based on the intention-to-treat GLMM analysis detailed in Table 2, the magnesium bisglycinate group had a statistically significantly greater between-group mean reduction in ISI scores from baseline to Week 4 [−3.9 (95% CI, −5.8 to −2.0)] compared to the placebo group [−2.3 (95% CI, −4.1 to −0.4)] (p = 0.049).”
- Study
- RCT
- Duration
- 4 weeks
- Interests
- An author is affiliated with a producer
- Dose studied
- magnesium bisglycinate, two capsules daily 30-60 minutes before bedtime, 250 mg elemental magnesium and 1523 mg glycine per day
- Population
- Adults aged 18 to 65 years in good health reporting poor sleep for more than four weeks (RIS score above 12); intention-to-treat, GLMM-adjusted for baseline ISI, age, sex, BMI and occupation
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Healthy adults aged 18 to 65 reporting poor sleep quality
- Participants
- 155
- Comparator
- placebo
- Duration
- 28 days
- Endpoints measured
- 27
magnesium(2+)